XML 115 R104.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental Financial Information - Cash Flows (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Cash flows from operating activities            
Net income (loss) $ 547.4   $ 332.7 $ 2,384.8 $ (171.8)  
Adjustments to reconcile net income (loss) to net cash flows from operating activities:            
Depreciation and amortization       40.5 38.9  
Right-of-use asset impairment   $ 26.8   24.8 0.0  
Equity-based compensation 42.4   18.7 122.0 78.3  
Non-cash performance allocations and incentive fees       (1,662.3) (239.6)  
Non-cash principal investment (income) loss       (458.3) 646.3  
Other non-cash amounts       20.7 (3.5)  
Purchases of investments       (178.0) (293.7)  
Proceeds from the sale of investments       533.8 233.6  
Payments of contingent consideration       (50.0) 0.0  
Changes in deferred taxes, net       449.1 4.7  
Change in due from affiliates and other receivables       (21.4) (8.3)  
Change in deposits and other       (23.3) (1.3)  
Change in accounts payable, accrued expenses and other liabilities       90.9 (57.5)  
Change in accrued compensation and benefits       17.3 73.0  
Change in due to affiliates       1.4 (31.5)  
Change in lease right-of-use assets and lease liabilities       5.9 (6.7)  
Change in deferred revenue       247.6 200.3  
Net cash provided by (used in) operating activities       1,302.4 (110.6)  
Cash flows from investing activities            
Purchases of fixed assets, net       (27.0) (37.3)  
Net cash used in investing activities       (17.8) (37.3)  
Cash flows from financing activities            
Borrowings under credit facilities       70.0 287.1  
Repayments under credit facilities       0.0 (300.6)  
Issuance of 4.625% subordinated notes due 2061, net of financing costs       484.1 0.0  
Payments on debt obligations       (231.5) (2.7)  
Proceeds from debt obligations, net of financing costs       87.5 20.5  
Payments of contingent consideration       (0.1) (0.3)  
Dividends to common stockholders       (266.7) (262.9)  
Payment of deferred consideration for Carlyle Holdings units       (68.8) (68.8)  
Contributions from non-controlling interest holders       57.2 24.2  
Distributions to non-controlling interest holders       (76.3) (53.5)  
Common shares repurchased (59.5)     (84.5) (26.4)  
Change in due to/from affiliates financing activities       21.8 40.9  
Net cash provided by financing activities       157.9 252.1  
Effect of foreign exchange rate changes       (26.2) 6.6  
Increase in cash, cash equivalents and restricted cash       1,416.3 110.8  
Cash, cash equivalents and restricted cash, beginning of period       989.6 828.0  
Cash, cash equivalents and restricted cash, end of period 2,405.9   938.8 2,405.9 938.8  
Reconciliation of cash, cash equivalents and restricted cash, end of period:            
Cash and cash equivalents 2,399.0   938.4 2,399.0 938.4 $ 987.6
Restricted cash 6.9   0.4 6.9 0.4 2.0
Total cash, cash equivalents and restricted cash, end of period 2,405.9   938.8 2,405.9 938.8 989.6
Cash and cash equivalents held at Consolidated Funds $ 134.8   377.8 134.8 377.8 148.6
MRE            
Cash flows from investing activities            
Proceeds from sale, net of cash sold       5.9 0.0  
Brazil management entity            
Cash flows from investing activities            
Proceeds from sale, net of cash sold       $ 3.3 0.0  
Subordinated Notes Due 2061            
Reconciliation of cash, cash equivalents and restricted cash, end of period:            
Interest rate (percent) 4.625%     4.625%    
Consolidated Operating Entities            
Cash flows from operating activities            
Net income (loss)       $ 2,383.9 (178.0)  
Adjustments to reconcile net income (loss) to net cash flows from operating activities:            
Depreciation and amortization       40.5 38.9  
Right-of-use asset impairment       24.8 0.0  
Equity-based compensation       122.0 78.3  
Non-cash performance allocations and incentive fees       (1,662.3) (239.6)  
Non-cash principal investment (income) loss       (470.7) 694.8  
Other non-cash amounts       20.7 (3.5)  
Purchases of investments       (250.9) (330.2)  
Proceeds from the sale of investments       559.1 258.3  
Payments of contingent consideration       (50.0) 0.0  
Changes in deferred taxes, net       449.1 4.7  
Change in due from affiliates and other receivables       (21.1) (8.7)  
Change in deposits and other       (23.3) (1.3)  
Change in accounts payable, accrued expenses and other liabilities       90.9 (57.5)  
Change in accrued compensation and benefits       17.3 73.0  
Change in due to affiliates       1.4 (31.5)  
Change in lease right-of-use assets and lease liabilities       5.9 (6.7)  
Change in deferred revenue       247.6 200.3  
Net cash provided by (used in) operating activities       1,484.9 491.3  
Cash flows from investing activities            
Purchases of fixed assets, net       (27.0) (37.3)  
Net cash used in investing activities       (17.8) (37.3)  
Cash flows from financing activities            
Borrowings under credit facilities       70.0 287.1  
Repayments under credit facilities       0.0 (300.6)  
Issuance of 4.625% subordinated notes due 2061, net of financing costs       484.1 0.0  
Payments on debt obligations       (231.5) (2.7)  
Proceeds from debt obligations, net of financing costs       87.5 20.5  
Payments of contingent consideration       (0.1) (0.3)  
Dividends to common stockholders       (266.7) (262.9)  
Payment of deferred consideration for Carlyle Holdings units       (68.8) (68.8)  
Contributions from non-controlling interest holders       13.1 24.2  
Distributions to non-controlling interest holders       (56.3) (52.5)  
Common shares repurchased       (84.5) (26.4)  
Change in due to/from affiliates financing activities       21.8 40.9  
Net cash provided by financing activities       (31.4) (341.5)  
Effect of foreign exchange rate changes       (19.4) (1.7)  
Increase in cash, cash equivalents and restricted cash       1,416.3 110.8  
Cash, cash equivalents and restricted cash, beginning of period       989.6 828.0  
Cash, cash equivalents and restricted cash, end of period $ 2,405.9   938.8 2,405.9 938.8  
Reconciliation of cash, cash equivalents and restricted cash, end of period:            
Cash and cash equivalents 2,399.0   938.4 2,399.0 938.4  
Restricted cash 6.9   0.4 6.9 0.4  
Total cash, cash equivalents and restricted cash, end of period 2,405.9   938.8 2,405.9 938.8 $ 989.6
Cash and cash equivalents held at Consolidated Funds $ 134.8   $ 377.8 134.8 377.8  
Consolidated Operating Entities | MRE            
Cash flows from investing activities            
Proceeds from sale, net of cash sold       5.9 0.0  
Consolidated Operating Entities | Brazil management entity            
Cash flows from investing activities            
Proceeds from sale, net of cash sold       $ 3.3 $ 0.0